Search

everythinglearnresearchcommunity

for

Search:↓

User considers trying Pyrilutamide for hair loss and itch relief. Another user shares positive experience with Pyrilutamide, no side effects.

Finasteride and Dutasteride used in combination with RU58841 and microneedling, as a treatment for hair loss. There was discussion on progress of the treatment and potential other methods to consider.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

The conversation is about purchasing dutasteride solution for mesotherapy, with a suggestion to make it using dutasteride capsules and oils. A user shared a link to a potential supplier and mentioned using dutasteride with microneedling.

The user switched from finasteride to DIY dutasteride mesotherapy and topical minoxidil due to side effects. They report improved well-being and no hair loss worsening after stopping finasteride.

Scalp micropigmentation as a treatment for hair loss, and the importance of choosing a reputable practitioner to get a natural look. Different treatments such as laser removal were also discussed in relation to long-term maintenance.

A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

The user is starting Dutasteride mesotherapy and seeks advice on whether to apply the solution immediately after microneedling or wait 12-24 hours. They couldn't find instructions for first-timers.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

User is seeking information on obtaining dutasteride vials for mesotherapy in the US, mentioning a closed source and lack of local clinic options.

The conversation is about a user considering reducing their dutasteride dose due to side effects like lower libido and watery semen. They plan to use dutasteride mesotherapy every three months to maintain hair while reducing systemic DHT suppression.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.